Evidence map›Paper›PMID 28024930›Full record

Trial reportAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2017

Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial.

Joachim H Ix, Ronit Katz, Nisha Bansal, Meredith Foster, Daniel E Weiner, Russell Tracy, Vasantha Jotwani, Jan Hughes-Austin, Dianne McKay, Francis Gabbai and 4 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Trial
  6. Trial
  7. Trial
  8. Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Trial
  9. Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Biomarkers of aging.Science China. Life sciences · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Joachim H IxDivision of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, CA; Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, CA; Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA. Electronic address: joeix@ucsd.edu.
Ronit KatzKidney Research Institute, Division of Nephrology, University of Washington, Seattle, WA.
Nisha BansalKidney Research Institute, Division of Nephrology, University of Washington, Seattle, WA.
Meredith FosterDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
Daniel E WeinerDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
Russell TracyDepartment of Pathology, University of Vermont, Burlington, VT.
Vasantha JotwaniDivision of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA.
Jan Hughes-AustinDepartment of Orthopedic Surgery, University of California San Diego, San Diego, CA.
Dianne McKayDivision of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, CA.
Francis GabbaiDivision of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, CA; Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, CA.
Chi-Yuan HsuDivision of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA.
Andrew BostomRhode Island Hospital, Providence, RI.
Andrew S LeveyDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
Michael G ShlipakGeneral Internal Medicine Section, San Francisco Veterans Affairs Hospital, San Francisco, CA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA.
Tufts Medical Center · USUniversity of California, San Diego · USUniversity of California, San Francisco · USUniversity of Washington · USRhode Island Hospital · USUniversity of Vermont · USVA San Diego Healthcare System · US

Funding

Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) TrialU01DK061700 · NIDDK · TUFTS MEDICAL CENTER · PI LEVEY, ANDREW S · 2001 to 2011
$29.0M
Kidney Tubular Damage and Dysfunction Identify a Novel Axis of Chronic Kidney DiseaseR01DK098234 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI IX, JOACHIM H, SHLIPAK, MICHAEL G · 2014 to 2023
$5.6M
NIDDK NIH HHS R01 DK098234NIDDK NIH HHS U01 DK061700
6 · The paper itself

Abstract

backgroundKidney tubulointerstitial fibrosis marks risk for allograft failure in kidney transplant recipients, but is poorly captured by estimated glomerular filtration rate (eGFR) or urine albumin-creatinine ratio (ACR). Whether urinary markers of tubulointerstitial fibrosis can noninvasively identify risk for allograft failure above and beyond eGFR and ACR is unknown. STUDY

designCase-cohort study. SETTING &

participantsThe FAVORIT (Folic Acid for Vascular Outcome Reduction in Transplantation) Trial was a randomized double-blind trial testing vitamin therapy to lower homocysteine levels in stable kidney transplant recipients. We selected a subset of participants at random (n=491) and all individuals with allograft failure during follow-up (cases; n=257). PREDICTOR: Using spot urine specimens from the baseline visit, we measured 4 urinary proteins known to correlate with tubulointerstitial fibrosis on biopsy (urine α OUTCOME: Death-censored allograft failure.

resultsIn models adjusted for demographics, chronic kidney disease risk factors, eGFR, and ACR, higher concentrations of urine A1M (HR per doubling, 1.73; 95% CI, 1.43-2.08) and MCP-1 (HR per doubling, 1.60; 95% CI, 1.32-1.93) were strongly associated with allograft failure. When additionally adjusted for concentrations of other urine fibrosis and several urine injury markers, urine A1M (HR per doubling, 1.76; 95% CI, 1.27-2.44]) and MCP-1 levels (HR per doubling, 1.49; 95% CI, 1.17-1.89) remained associated with allograft failure. Urine procollagen type III and type I levels were not associated with allograft failure. LIMITATIONS: We lack kidney biopsy data, BK titers, and HLA antibody status.

conclusionsUrine measurement of tubulointerstitial fibrosis may provide a noninvasive method to identify kidney transplant recipients at higher risk for future allograft failure, above and beyond eGFR and urine ACR.

Indexed as

Kidney TransplantationBiomarkersCohort StudiesDouble-Blind MethodFemaleFibrosisGlomerular Filtration RateHumansKidneyMaleMiddle AgedPostoperative ComplicationsRenal InsufficiencyRisk AssessmentBiomarkersallograft failurebiomarkercase-cohortend-stage renal disease (ESRD)Fibrosisinflammationkidney transplantationkidney transplant recipient (KTR)monocyte chemoattractant protein 1 (MCP-1)risk factortubulo-interstitial fibrosisurinary markerα(1)-microglobulin (A1M)

Identifiers

PMID28024930
PMCPMC7321838
OpenAlexW2564572385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.